ATE247717T1 - Apoliporotein e polymorphismen und behandlung der alzheimerkrankheit - Google Patents

Apoliporotein e polymorphismen und behandlung der alzheimerkrankheit

Info

Publication number
ATE247717T1
ATE247717T1 AT95916530T AT95916530T ATE247717T1 AT E247717 T1 ATE247717 T1 AT E247717T1 AT 95916530 T AT95916530 T AT 95916530T AT 95916530 T AT95916530 T AT 95916530T AT E247717 T1 ATE247717 T1 AT E247717T1
Authority
AT
Austria
Prior art keywords
pct
apoliporotein
polymorphisms
alzheimer
disease
Prior art date
Application number
AT95916530T
Other languages
English (en)
Inventor
Judes Poirier
Original Assignee
Univ Mcgill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mcgill filed Critical Univ Mcgill
Application granted granted Critical
Publication of ATE247717T1 publication Critical patent/ATE247717T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
AT95916530T 1994-04-27 1995-04-26 Apoliporotein e polymorphismen und behandlung der alzheimerkrankheit ATE247717T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9408465A GB9408465D0 (en) 1994-04-27 1994-04-27 Apolipoprotein e polymorphism & treatment of alzheimer's disease
PCT/CA1995/000240 WO1995029257A2 (en) 1994-04-27 1995-04-26 Apolipoprotein e polymorphism and treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
ATE247717T1 true ATE247717T1 (de) 2003-09-15

Family

ID=10754293

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95916530T ATE247717T1 (de) 1994-04-27 1995-04-26 Apoliporotein e polymorphismen und behandlung der alzheimerkrankheit

Country Status (13)

Country Link
US (1) US5935781A (de)
EP (1) EP0804615B1 (de)
JP (1) JP3285585B2 (de)
AT (1) ATE247717T1 (de)
AU (1) AU693193B2 (de)
CA (1) CA2188933C (de)
DE (1) DE69531557T2 (de)
FI (1) FI964284A (de)
GB (1) GB9408465D0 (de)
MX (1) MX9605176A (de)
NO (1) NO964543L (de)
NZ (1) NZ284412A (de)
WO (1) WO1995029257A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9408465D0 (en) * 1994-04-27 1994-06-22 Univ Mcgill Apolipoprotein e polymorphism & treatment of alzheimer's disease
US7049078B2 (en) 1994-04-27 2006-05-23 Judés Poirier Apolipoprotein E polymorphism and treatment of alzheimer's disease
US6022683A (en) * 1996-12-16 2000-02-08 Nova Molecular Inc. Methods for assessing the prognosis of a patient with a neurodegenerative disease
US5767337A (en) * 1995-07-31 1998-06-16 Duke University Creation of human apolipoprotein E isoform specific transgenic mice in apolipoprotein deficient "knockout" mice
GB9525481D0 (en) * 1995-12-13 1996-02-14 Royston M C Novel method
ES2115553B1 (es) * 1996-10-23 1999-02-16 Boehringer Ingelheim Espana Metodo para detectar la presencia de polimorfismos de dna, estuche de ensayo y acidos nucleicos recombinantes correspondientes.
FR2765591B1 (fr) * 1997-07-01 2002-08-09 Pasteur Institut Procede de diagnostic de la maladie d'alzheimer
AU9454098A (en) * 1997-09-24 1999-04-12 Nova Molecular, Inc. Methods for increasing apoe levels for the treatment of neurodegenerative disease
ES2142248B1 (es) * 1997-11-20 2000-11-16 Univ Madrid Autonoma Polimorfismos en el promotor del gen humano de la apolipoproteina e, y sus usos para aplicaciones diagnosticas y terapeuticas.
US6251587B1 (en) 1997-12-16 2001-06-26 Nova Molecular, Inc. Method for determining the prognosis of a patient with a neurological disease
AU3979099A (en) 1998-05-11 1999-11-29 Philadelphia Health & Education Corporation (mct-1), a human oncogene
EP1117840A1 (de) * 1998-10-01 2001-07-25 Variagenics, Inc. Verfahren zur erkennung oder behandlung von personen mit einem risiko für neuronale erkrankungen durch die bestimmung von gpiiia or gpiib allelvarianten
US20040209849A1 (en) * 1998-11-27 2004-10-21 Sanochemia Pharmazeutika Aktiengesellschaft Use of effectors of the central cholinergic nervous system for treatment of delirium
US6573049B1 (en) 1999-07-26 2003-06-03 Nuvelo, Inc. Genotyping of the paraoxonase 1 gene for prognosing, diagnosing, and treating a disease
US6432643B1 (en) * 1999-10-22 2002-08-13 Duke University Method of determining Alzheimer's disease risk using apolipoprotein E4 genotype analysis in combination with decreased estrogen levels
EP1113081A1 (de) * 1999-12-28 2001-07-04 Institut Pasteur De Lille Zusammenhang des bekannten Gens CP2/LSF/LBP-1 mit Alzheimer
US6453244B1 (en) * 2000-02-10 2002-09-17 Stanford University Detection of polymorphisms by denaturing high-performance liquid chromatography
US20020019746A1 (en) * 2000-03-16 2002-02-14 Rienhoff Hugh Y. Aggregating persons with a select profile for further medical characterization
WO2001082928A1 (en) 2000-05-01 2001-11-08 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US20020010552A1 (en) * 2000-05-26 2002-01-24 Hugh Rienhoff System for genetically characterizing an individual for evaluation using genetic and phenotypic variation over a wide area network
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20040106124A1 (en) * 2001-02-12 2004-06-03 Murphy Greer M. Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4 and for improving the terapeutic response of humans having major depression and carrying the gene for apolipoprotein e4
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20040005566A1 (en) * 2002-07-02 2004-01-08 Genelink, Inc. Kits and methods for assessing cardiovascular health
AU2005263578B2 (en) 2004-07-16 2010-09-02 Proteosys Ag Muscarinic antagonists with PARP and SIR modulating activity as agents for inflammatory diseases
ES2645816T3 (es) 2006-04-03 2017-12-07 Accera, Inc. Uso de compuestos cetogénicos para el tratamiento de la alteración de la memoria asociada a la edad
WO2008060400A2 (en) * 2006-11-15 2008-05-22 Sirtris Pharmaceuticals, Inc. Sirtuin polymorphisms and methods of use thereof
PT2650382E (pt) 2007-07-31 2016-01-14 Accera Inc Utilização de testagem genómica e compostos cetogénicos para o tratamento de função cognitiva reduzida
KR101734152B1 (ko) * 2008-07-03 2017-05-11 액세라인크 신경계 장애의 치료를 위한 아세토아세테이트의 모노글리세리드 및 유도체
US8105809B2 (en) * 2008-07-03 2012-01-31 Accera, Inc. Enzymatic synthesis of acetoacetate esters and derivatives
WO2010081823A1 (en) 2009-01-13 2010-07-22 Proteosys Ag Pirenzepine as otoprotective agent
WO2011006144A1 (en) 2009-07-10 2011-01-13 Martek Biosciences Corporation Methods of treating and preventing neurological disorders using docosahexaenoic acid
US20190338363A1 (en) * 2016-12-18 2019-11-07 Selonterra, Inc. Use of apoe4 motif-mediated genes for diagnosis and treatment of alzheimer's disease
EP3628315A1 (de) 2018-09-28 2020-04-01 Université de Caen Normandie Kombination aus acetylcholinesterase-inhibitor und 5-ht4-rezeptoragonist als neuroprotektives mittel zur behandlung von neurodegenerativen krankheiten

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69333461T2 (de) * 1992-10-13 2005-03-24 Duke University VERFAHREN ZUM nachweis der Alzheimer Krankheit
JPH09500645A (ja) * 1993-07-22 1997-01-21 ワーナー−ランバート・コンパニー 制御放出タクリン薬物送達システムおよびその製造方法
US5643960A (en) * 1994-04-15 1997-07-01 Duke University Method of delaying onset of alzheimer's disease symptoms
GB9408465D0 (en) * 1994-04-27 1994-06-22 Univ Mcgill Apolipoprotein e polymorphism & treatment of alzheimer's disease
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
GB9415073D0 (en) * 1994-06-27 1994-09-14 Smithkline Beecham Plc Novel method
GB9414624D0 (en) * 1994-07-20 1994-09-07 Smithkline Beecham Plc Novel method

Also Published As

Publication number Publication date
WO1995029257A2 (en) 1995-11-02
FI964284A (fi) 1996-12-23
DE69531557D1 (de) 2003-09-25
EP0804615B1 (de) 2003-08-20
GB9408465D0 (en) 1994-06-22
NO964543L (no) 1996-12-20
CA2188933A1 (en) 1995-11-02
EP0804615A1 (de) 1997-11-05
MX9605176A (es) 1998-06-30
AU2300695A (en) 1995-11-16
DE69531557T2 (de) 2004-06-17
CA2188933C (en) 2000-11-14
WO1995029257A3 (en) 1995-11-23
NO964543D0 (no) 1996-10-25
NZ284412A (en) 2000-01-28
US5935781A (en) 1999-08-10
JPH10500288A (ja) 1998-01-13
FI964284A0 (fi) 1996-10-24
JP3285585B2 (ja) 2002-05-27
AU693193B2 (en) 1998-06-25

Similar Documents

Publication Publication Date Title
ATE247717T1 (de) Apoliporotein e polymorphismen und behandlung der alzheimerkrankheit
DE69729473D1 (de) Pharmazeutisch-genetische verfahren zur verwendung bei der behandlung von krankheiten des nervensystems
Wellenreuther et al. Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma.
ATE211129T1 (de) Inhibitoren von beta-amyloid-protein-herstellung
Holmes et al. Apolipoprotein E: non-cognitive symptoms and cognitive decline in late onset Alzheimer's disease.
LV12558A (lv) Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
BR9811260A (pt) Pequenas moléculas úteis no tratamento de doença inflamatória
ATE186305T1 (de) Perfluoroalkyll ketone, inhibitoren von elastase und prozess zur deren herstellung
DE69526120D1 (de) Verwendung von nebivolol als anti-atherogenisches mittel
ATE198050T1 (de) Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
Steinlein et al. Neuronal nicotinic acetylcholine receptor α4 subunit (CHRNA4) and panic disorder: An association study
EP0830139A4 (de) Modifizierte myelin proteinmoleküle
Raza et al. A novel homozygous nonsense mutation in the PVRL4 gene and expansion of clinical spectrum of EDSS1
DE69705936D1 (de) Teil der intronsequenz des von hippel-lindau(vhl)-gens und seine verwendung zur krankheitsdiagnose
GB9610281D0 (en) Diagnostic method and apparatus
WO1997042347A3 (en) 5-lipoxygenase gene polymorphisms and their use in classifying patients
DE59509370D1 (de) Mittel zur beeinflussung von störungen der knochenbildung, das kaliumcitrate und/oder kaliumlactate und/oder kaliummalate enthält
Rauramaa et al. The Rsal Polymorphism in the α-Fibrinogen Gene and Response of Plasma Fibrinogen to Physical Training
NZ228068A (en) Brominated or chlorinated allylamines and their pharmaceutical compositions
DE69701258D1 (de) Verwendung von benzonaphtalene-derivaten zur herstellung eines arzneimittels zur behandlung von krankheiten des nervensystems
AU2002358580A1 (en) Methods of identifying genetic risk for and evaluating treatment of alzheimer's disease by determing single nucleotide polymorphisms
DE60224778D1 (de) Zusammensetzungen und Verfahren zur Behandlung und zur Detektion von proliferativen Störungen die mit der Überexpression des menschlichen "Transketolase like-1" gens in Zusammenhang stehen
AU5052899A (en) Genetic polymorphisms in the human neurokinin 1 receptor gene and their uses in diagnosis and treatment of diseases
Akar et al. Factor V 1691G-A mutation and high factor VIII levels in a patient with intracardiac thrombosis
HUP0100409A2 (hu) A kedélybetegség génje

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties